Navigation Links
Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
Date:4/30/2008

Transaction also provides the Company and investor an option to sell or

purchase additional $67.5 million in securities

SEATTLE, April 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq: CTIC; MTA) today announced that it has entered into agreements to sell units of securities for approximately $64.5 million, including new Series E Convertible Preferred Stock (the "Preferred Stock"), 13.5% Convertible Senior Notes due 2014 (the "Notes") and warrants to purchase shares of common stock, no par value (the "Common Stock") to a single institutional investor. The aggregate price per unit was $0.3475 cents above the closing bid of $0.79 per share or $1.14 per unit. Also included is a one- year right for such investor to purchase up to $67.5 million of such securities in the future.

The 9,000 shares of Preferred Stock are convertible into 11,392,405 shares of Common Stock. The Preferred Stock, representing $9 million in stated value, can also be exchanged by such investor after 30 days into Notes. The $36 million initial principal amount of Notes bear interest at 13.5% per annum and are convertible at any time for shares of CTI common stock. The Notes feature a make-whole provision upon conversion entitling the holder to receive a fixed amount, less any interest paid before conversion. The Company expects to receive net proceeds of approximately $28.125 million from the initial closing of the offering. The Notes will rank equal in right of payment with all existing and future unsecured senior indebtedness of CTI.

The investor will also receive warrants to purchase 28.4 million shares of common stock with an exercise price of $0.95 per share (equal to 120% of today's closing bid
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
2. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
3. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
4. Cell Therapeutics, Inc. Announces Filing of Form 10-K
5. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
6. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
7. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
8. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
9. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
11. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... SAN JOSE, Calif. , Aug. 20, 2014 ... UCSD highlights the transformative collaboration between the school,s ... (IoT).  As part of the Intel® Software Academic ... between computer sciences and the human body.  ... The study exhibits the work of ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced two ... adding to the company’s extensive line-up of HPLC ... operating environment, and full automation, the i-Series provides ... conventional to ultra-high-speed analysis. , The ... so users can begin building the lab of ...
(Date:8/19/2014)... La Jolla, CA (PRWEB) August 19, 2014 ... the toll Parkinson’s disease can take on an individual. ... tremoring extremities, decreased facial expression, problems swallowing and severe ... due to the dying off of dopamine producing neurons ... retain themselves from a disease that slowly and progressively ...
(Date:8/19/2014)...   Synthetic Biologics, Inc. (NYSE MKT: ... and drug programs targeting specific pathogens that cause ... novel C. difficile development program will ... Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September ... Synthetic Biologics, Senior Vice President, Research ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... they are riddled with defects, bulk crystalline materials never ... are so small there,s no room for defects. ("Nano" ... Yet while nanocrystalline materials may approach ideal strength in ... a limited ability to withstand large internal strains before ...
... Oct. 20 Humanitarian, Dr. Gary Michelson,is "making ... Aimee Gilbreath, Executive Director of Found Animals Foundation ... Found Animals and its strategic partner the ... the launch of The Michelson Prize in,Reproductive Biology ...
... 20 Idenix,Pharmaceuticals, Inc., (Nasdaq: IDIX ) announced ... third quarter of 2008 on Thursday, October,30, 2008 after ... the issuance of the press release, Idenix,management will host ... October,30, 2008 to discuss the company,s financial results for ...
Cached Biology Technology:Engineering nanoparticles for maximum strength 2Engineering nanoparticles for maximum strength 3Engineering nanoparticles for maximum strength 4Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 2Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 3Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 4
(Date:8/20/2014)... at Huntsman Cancer Institute (HCI) at the University of ... gene that encodes BCR-ABL, the unregulated enzyme driving the ... American Cancer Society, nearly 6,000 new cases of CML ... use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL and ... cure CML but control it in a way that ...
(Date:8/20/2014)... University, the Wellcome Trust Sanger Institute and the Swiss ... Mycobacterium pinnipedii from skeletons found in Peru which ... a relative of the TB bacterium that affects seals ... researchers assume that seals carried the pathogens from Africa ... was unexpected" comments Sebastien Gagneux, from the Swiss Tropical ...
(Date:8/20/2014)... 19, 2014 -- Bay Area Lyme Foundation, which aims ... to cure, applauds new research published in an upcoming ... and Tick-borne Diseases . The findings show that ... active throughout the year, making the threat of Lyme ... California Department of Public Health (CDPH) Vector-borne Disease Section ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... treat tumors by selectively targeting and killing the malignant ... access journal PLoS Medicine, has applied the approach to ... form of brain tumour, growing very quickly before symptoms ... of diagnosis. , Working in mice, Alexander Levitzki ...
... There was a low rate of life-threatening adverse ... first responders to a bioterrorism incident, possibly attributable ... according to a study in the December 7 ... smallpox in the United States ceased in 1971, ...
... Bees have a much more sophisticated visual system than ... London) study in which bees were able to solve ... brains resolve one of the most difficult challenges of ... of illumination - by suggesting that bees solve this ...
Cached Biology News:Preclinical study of a new brain tumor therapy 2Serious adverse reactions to smallpox vaccine appear to be limited 2Bees solve complex colour puzzles 2
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
... Immunogen: ... region encompassing the human, mouse, ... Accession Number: ... Assurance: Routinely evaluated by ...
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Biology Products: